The study of antidepressant properties of new 1,2,3-triazolo-1,4-benzodiazepine derivatives
DOI:
https://doi.org/10.24959/nphj.24.144Keywords:
triazolobenzodiazepine derivatives; forced swim test; tail suspension test; antidepressant activityAbstract
Anxiety-depressive disorders are among the most common mental health conditions and often cause significant functional impairment, affecting a person’s quality of life. Research conducted in recent years indicate the importance of studying and searching for new substances based on benzodiazepines, in particular triazolobenzodiazepines, for the treatment of anxiety states and disorders, as well as determining the presence of other biological activities of these compounds.
Aim. To study the antidepressant activity of new derivatives of 1,2,3-triazolo-1,4-benzodiazepines in the Porsolt forced swim and tail suspension tests.
Materials and methods. The antidepressant activity of new 1,2,3-triazolo-1,4-benzodiazepine derivatives under the code MA-252, MA-253, MA-254, MA-255 and MA-261 was studied in the Porsolt forced swim and tail suspension tests. The following behavioral reactions, such as the latent period of the first immobility (more than 5 seconds), the total duration of immobility (staying in a stationary state), the number of immobile episodes, were recorded.
Results and discussion. During the study, a decrease in the total duration of immobility, the main indicator of “despair” of animals, and an increase in the latent period of the first immobility were monitored. It may indicate the manifestation of antidepressant properties of new 1,2,3-triazolo-1,4-benzodiazepine derivatives. The indicator of the antidepressant activity in groups of animals administered MA-253, MA-254 and MA-255 derivatives in all doses was higher among the groups studied. The depression index was the lowest when MA-253 and MA-254 derivatives were used in the dose of 1 mg/kg, and was not statistically significantly different from that in the group receiving imipramine in the dose of 25 mg/kg. According to the results of the tail suspension test, 1,2,3-triazolo-1,4-benzodiazepine derivatives MA-253, MA-254 and MA-255 showed a significant decrease in the total duration of immobilization by 69.4 %, 47.1 % and 33.1 %, respectively, in relation to the control group (p<0.05), as well as an increase in the latent period of the onset of the first immobility episode by several times.
Conclusions. A decrease in the duration of immobility in mice injected with 1,2,3-triazolo-1,4-benzodiazepine derivatives gives grounds to draw a conclusion that animals develop a state of “behavioral despair” and exhibit antidepressant properties.
References
Ravindran, L. N., Stein, M. B. (2010). The Pharmacologic Treatment of Anxiety Disorders: A Review of Progress. The Journal of Clinical Psychiatry, 71(7), 14308. doi: 10.4088/JCP.10r06218blu.
Santomauro, D. F., Mantilla Herrera, A. M., Shadid, J., Zheng, P., Ashbaugh, C., Pigott, D. M. et al. (2021). Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. The Lancet, 398(10312), 1700–1712. doi: 10.1016/S0140-6736(21)02143-7.
Khaustova, O. (2023). Tryvozhno-depresyvni rozlady v umovakh dystresu viiny v Ukraini. health-ua.com. Retrieved January, 17, 2024. Available at: https://health-ua.com/article/71710-trivozhnodepresivn-rozladi-vumovah-distresu-vjni-vukran.
Haq, F. U., Shoaib, M., Ali Shah, S. W., Hussain, H., Zahoor, M., Ullah, R. et al. (2023). Antidepressant Activities of Synthesized Benzodiazepine Analogues in Mice. Brain Sciences, 13(3), 523. doi: 10.3390/brainsci13030523.
Bushnell, G. A., Stürmer, T., Gaynes, B. N., Pate, V., Miller, M. (2017). Simultaneous Antidepressant and Benzodiazepine New Use and Subsequent Long-term Benzodiazepine Use in Adults With Depression, United States, 2001-2014. JAMA psychiatry, 74(7), 747–755. doi: 10.1001/jamapsychiatry.2017.1273.
Lim, B., Sproule, B. A., Zahra, Z., Sunderji, N., Kennedy, S. H., Rizvi, S. J. (2020). Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology. International Clinical Psychopharmacology, 35(5), 243. doi: 10.1097/YIC.0000000000000316.
Hryhoriev, M. (2023). Retrospective analysis of the use of benzodiazepines in anxiety disorders. Ukrainian Scientific Medical Youth Journal, 136(1), 125–130. doi: 10.32345/USMYJ.1(136).2023.125-130.
Sanabria, E., Cuenca, R. E., Esteso, M. Á., Maldonado, M. (2021). Benzodiazepines: Their Use either as Essential Medicines or as Toxics Substances. Toxics, 9(2), 25. doi: 10.3390/toxics9020025.
Poleszak, E., Szopa, A., Bogatko, K., Wyska, E., Wośko, S., Świąder, K. et al. (2019). Antidepressant-Like Activity of Typical Antidepressant Drugs in the Forced Swim Test and Tail Suspension Test in Mice Is Augmented by DMPX, an Adenosine A2A Receptor Antagonist. Neurotoxicity Research, 35(2), 344–352. doi: 10.1007/s12640-018-9959-2.
Amouzad Mahdirejei, H., Peeri, M., Azarbayjani, M. A., Masrour, F. F. (2023). Diazepam and exercise training combination synergistically reduces lipopolysaccharide-induced anxiety-like behavior and oxidative stress in the prefrontal cortex of mice. NeuroToxicology, 97, 101–108. doi: 10.1016/j.neuro.2023.06.004.
Belhassan, A., Zaki, H., Benlyas, M., Lakhlifi, T., Bouachrine, M. (2019). Study of novel triazolo-benzodiazepine analogues as antidepressants targeting by molecular docking and ADMET properties prediction. Heliyon, 5(9). doi: 10.1016/j.heliyon.2019.e02446.
Sahin, Z. (2023). Assessment of commonly used tests in experimental depression studies according to behavioral patterns of rodents. Medical Review, 3(6), 526–531. doi: 10.1515/mr-2023-0018.
Ueno, H., Takahashi, Y., Murakami, S., Wani, K., Matsumoto, Y., Okamoto, M. et al. (2022). Effect of simultaneous testing of two mice in the tail suspension test and forced swim test. Scientific Reports, 12, 9224. doi: 10.1038/s41598-022-12986-9.
Cryan, J. F., Mombereau, C., Vassout, A. (2005). The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice. Neuroscience & Biobehavioral Reviews, 29(4), 571–625. doi: 10.1016/j.neubiorev.2005.03.009.
Botsula I. V., Kireiev I. V., Koshovyi O. M., Chebanov V. A. (2023). Vplyv novykh pokhidnykh 1,2,3-triazolo-1,4-benzodiazepiniv na miazovyi tonus hryzuniv Aktualni problemy farmatsii ta medytsyny: nauka i praktyka, 16(3), 217–222. doi: 10.14739/2409-2932.2023.3.287999.
Botsula, I., Sсhavikin, J., Heinämäki, J., Laidmäe, I., Mazur, M., Raal, A. et al. (2024). Application of nanofiber-based drug delivery systems in improving anxiolytic effect of new 1,2,3-triazolo-1,4-benzodiazepine derivatives. European Journal of Pharmaceutical Sciences, 195, 106712. doi: 10.1016/j.ejps.2024.106712.
Mazur, M. O., Zhelavskyi, O. S., Zviagin, E. M., Shishkina, S. V., Musatov, V. I., Kolosov, M. A. et al. (2021). Effective microwave-assisted approach to 1,2,3-triazolobenzodiazepinones via tandem Ugi reaction/catalyst-free intramolecular azide-alkyne cycloaddition. Beilstein Journal of Organic Chemistry, 17, 678–687. doi: 10.3762/bjoc.17.57.
Directive 2010/63/EU of the European Parliament and of the Council on the protection of animals used for scientific purposes. (2010). Official Journal of the European Communities, L 256, 33–79.
Guide for the Care and Use of Laboratory Animals: Eighth Edition. (2011). Washington, D.C. : National Academies Press. doi: 10.17226/12910.
Porsolt, R. D., Anton, G., Blavet, N., Jalfre, M. (1978). Behavioural despair in rats: A new model sensitive to antidepressant treatments. European Journal of Pharmacology, 47(4), 379–391. doi: 10.1016/0014-2999(78)90118-8.
Podolskyi, I. M. (2019). Dynamika rozvytku antydepresyvnoho efektu atrystaminu pry bahatorazovomu vvedenni. Klinichna farmatsiia, 23(1), 19–25. doi: 10.24959/cphj.19.1488.
Pruhlo, Ye. S. (2018). Antydepresyvna aktyvnist benzylidenovykh pokhidnykh 4-amino-5-(alkil-, aryl-, heteryl)-1,2,4-triazol-3-tioniv. Aktualni problemy farmatsii ta medytsyny: nauka i praktyka, 11, 3, 296-302. doi: 10.14739/2409-2932.2018.3.145228.
Liu, S., Xu, S., Wang, Z., Guo, Y., Pan, W., Shen, Z. (2018). Anti-Depressant-Like Effect of Sinomenine on Chronic Unpredictable Mild Stress-Induced Depression in a Mouse Model. Medical Science Monitor, 24, 7646–7653. doi: 10.12659/MSM.908422.
Sewell, F., Waterson, I., Jones, D., Tricklebank, M. D., Ragan, I. (2021). Preclinical screening for antidepressant activity – shifting focus away from the Forced Swim Test to the use of translational biomarkers. Regulatory Toxicology and Pharmacology, 125, 105002. doi: 10.1016/j.yrtph.2021.105002.
Methuku, K. R., Li, X., Cerne, R., Gleason, S. D., Schkeryantz, J. M., Tiruveedhula, V. V. N. P. B. et al. (2018). An antidepressant-related pharmacological signature for positive allosteric modulators of α2/3-containing GABAA receptors. Pharmacology Biochemistry and Behavior, 170, 9–13. doi: 10.1016/j.pbb.2018.04.009.
El Zahaf, N. A., Elhwuegi, A. S. (2014). The effect of GABAmimetics on the duration of immobility in the forced swim test in albino mice. Libyan Journal of Medicine, 9(1), 23480. doi: 10.3402/ljm.v9.23480.
Cárdenas, J., Reyes-Pérez, V., Hernández-Navarro, M., Dorantes-Barrón, A., Almazán, S., Estrada-Reyes, R. (2017). Anxiolytic- and antidepressant-like effects of an aqueous extract of Tanacetum parthenium L. Schultz-Bip (Asteraceae) in mice. Journal of ethnopharmacology, 200, 22-30. doi: 10.1016/j.jep.2017.02.023.
Steru, L., Chermat, R., Thierry, B., Simon, P. (1985). The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology, 85(3), 367–370. doi: 10.1007/BF00428203.
Neis, V. B., Rosado, A. F., Olescowicz, G., Moretti, M., Rosa, P. B., Platt, N., Rodrigues, A. L. S. (2020). The involvement of GABAergic system in the antidepressant-like effect of agmatine. Naunyn-Schmiedeberg’s Archives of Pharmacology, 393(10), 1931–1939. doi: 10.1007/s00210-020-01910-5.
Broderick, P. A. (1997). Alprazolam, diazepam, yohimbine, clonidine: In vivo CA1, hippocampal norepinephrine and serotonin release profiles under chloral hydrate anesthesia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 21(7), 1117–1140. doi: 10.1016/S0278-5846(97)00103-6.
Möhler, H. (2012). The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology, 62(1), 42–53. doi: 10.1016/j.neuropharm.2011.08.040.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
